Speedy review for pioneering drugs: understanding Japan's new Sakigake process
This article was originally published in SRA
Executive Summary
Sakigake is becoming an increasingly familiar buzzword in Japan and beyond following the first unveiling of the proposals by the country's drugs and devices regulator, the PMDA, around the middle of last year1.